Vanda reports data from Phase II acute performance anxiety therapy trial

Vanda Pharmaceuticals has reported data from a Phase II clinical trial of VQW-765 for the treatment of acute performance anxiety.

The placebo-controlled, randomised, multicentre, double-blind study (Study 2201) has been designed for assessing VQW-765’s efficacy and safety in performance anxiety patients.